Follow the conference on X #AntibioticResearchUK
Join us on September 18th, 2025, at the Wellcome Collection in London and online, for a conference focused on advancing the understanding and treatment of chronic and recurrent urinary tract infections (UTIs). This year, we’re excited to explore new developments that offer hope to patients and caregivers.
Around 2.8 million people experience UTIs in the UK every year. They cause significant disruption to daily life, particularly for those with chronic or recurring UTIs. They are also one of the most common causes of sepsis, a life-threatening condition. One of the most frequent infections seen in clinical practice in the UK, UTIs comprise a major societal health burden across all populations, particularly older women. Yet misdiagnosis and under-treatment are frequent issues, leading to some infections becoming resistant to antibiotics, further limiting treatment options. The charity Antibiotic Research UK deals directly with people affected by this.
Antibiotic Research UK is holding this conference to help, support and inform all those involved in UTIs, whether personally affected or working in research or healthcare. Antimicrobial resistance (AMR) is a growing threat in treating UTIs, and this major conference brings together clinical/research experts in the UTI field, with compelling, insightful and informative personal, patient experience of UTIs, to understand more about what needs to be done to tackle this national challenge.
This event builds on our successful 2024 conference, which was rated “excellent” by over 90% of delegates surveyed, and reached hunreds of registered clinicians, researchers, patients, policymakers, industry representatives, and media.
Our 2025 theme focuses on the frontiers of research and treatment for UTIs. Antibiotic Research UK will also present a new study revealing what research areas patients want prioritised. Through a series of expert talks, panel discussions, and patient stories, we will once again foster a sense of community while driving forward the conversation on overcoming these challenging infections.
Key Highlights
Expert Speakers: Hear from leading researchers on new approaches to testing and treating UTIs.
Patient Advocacy: Engage with patient advocates who will share their personal journeys and insights into different treatments.
Antibiotic Research UK Updates: Learn about patients’ research priorities, as we announce results of our patient Priority Setting Partnership, supported by the James Lind Alliance, together with our partners The Urology Foundation and Bladder Health UK.
Who Should Attend?
Patients: Gain insights and connect with others facing similar challenges.
Healthcare Professionals: Expand your knowledge with the latest research and treatment options as well as support your continuing professional development (CDP). This conference provides 5 hours training for CPD, subject to peer group approval for revalidation purposes.
Researchers and Academics: Explore collaborative opportunities and share your work.
Industry: Engage your healthcare audiences and peers
Donors and Supporters: Learn about our mission and the impact of your contributions.
Media: Hear about the latest advancements in the field.
Student/Patient Tickets: We look forward to welcoming and learning from students and patients, a subsidised ticket of £15.00 (£10 on Early Bird) is available. You may be asked for evidence of your student / patient status after registering.
Early Bird Rates: We have opened for bookings with Early Bird Discounts until the end of May 2025
Students or patients - £10.00 + VAT, will increase to £15.00 + VAT
Healthcare Professionals, academics & non profits - £75.00 + VAT, will increase to £85.00 + VAT
Commercial organisations - £125.00 + VAT, will increase to £150.00 + VAT
Unable to attend the full day? Don’t worry. This virtual conference will be recorded, giving you the flexibility to dip in and out throughout the day and catch up with anything you miss later. Find out more about virtual attendance.
This event has been financially supported, in part, by Corporate Sponsorship from Pfizer Ltd and an unrestricted grant from A. Menarini Farmaceutica Internazionale SRL. Supporting organisations have no control over content. All editorial control has been retained by Antibiotic Research UK.
This event is CPD Certified.
